Exicure (XCUR) Common Equity (2016 - 2026)
Exicure's (XCUR) quarterly Common Equity came in at $2.1 million in Q1 2026, down 81.57% YoY from $11.4 million in Q1 2025, and down 46.56% on a QoQ basis from $3.9 million in Q4 2025.
Exicure (XCUR) Common Equity (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Common Equity data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Common Equity fell 81.57% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 81.57% YoY) and the FY2025 annual result came in at $3.9 million, down 42.03% from the prior year.
- Common Equity eased to $2.1 million in Q1 2026, from $3.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $14.9 million in Q4 2022 to a low of -$3.7 million in Q3 2022.
- A 5-year average of $5.5 million and a median of $3.9 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity plunged 126.48% — and 2023, when it soared 734.48%.
- Tracing XCUR's Common Equity over 5 years: stood at $14.9 million in 2022, then sank by 79.69% to $3.0 million in 2023, then soared by 123.42% to $6.8 million in 2024, then sank by 42.03% to $3.9 million in 2025, then sank by 46.56% to $2.1 million in 2026.
- The last three Common Equity figures came in at $2.1 million (Q1 2026), $3.9 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Exicure | 8.41 Mn | 8.41 Mn | - | 977,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.10 Mn |
| Dec 31, 2025 | 3.93 Mn |
| Sep 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | 8.86 Mn |
| Mar 31, 2025 | 11.38 Mn |
| Dec 31, 2024 | 6.77 Mn |
| Sep 30, 2024 | 1.55 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 2.21 Mn |
| Dec 31, 2023 | 3.03 Mn |
| Sep 30, 2023 | 4.50 Mn |
| Jun 30, 2023 | 9.71 Mn |
| Mar 31, 2023 | 14.62 Mn |
| Dec 31, 2022 | 14.92 Mn |
| Sep 30, 2022 | -3.70 Mn |
| Jun 30, 2022 | 1.16 Mn |
| Mar 31, 2022 | 3.24 Mn |
| Dec 31, 2021 | 11.23 Mn |
| Sep 30, 2021 | 13.98 Mn |
| Jun 30, 2021 | 36.64 Mn |